6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Known O
hypersensitivity B-OSE_Labeled_AE
to O
amphetamine O
products O
or O
other O
ingredients O
of O
VYVANSE O
[ O
see O
Contraindications O
( O
4 O
) O
] O
* O
Hypertensive B-NonOSE_AE
Crisis I-NonOSE_AE
When O
Used O
Concomitantly O
with O
Monoamine O
Oxidase O
Inhibitors O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
* O
Drug B-OSE_Labeled_AE
Dependence I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
and O
Drug O
Abuse O
and O
Dependence O
( O
9.2 O
, O
9.3 O
) O
] O
* O
Serious O
Cardiovascular B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Blood B-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
and O
Heart O
Rate O
Increases I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Psychiatric B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Suppression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Growth I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Vasculopathy I-OSE_Labeled_AE
, O
including O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
phenomenon I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Serotonin B-NonOSE_AE
Syndrome I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
at O
a O
rate O
at O
least O
twice O
placebo O
) O
in O
children O
, O
adolescents O
, O
and/or O
adults O
with O
ADHD O
were O
anorexia O
, O
anxiety O
, O
decreased O
appetite O
, O
decreased O
weight O
, O
diarrhea O
, O
dizziness O
, O
dry O
mouth O
, O
irritability O
, O
insomnia O
, O
nausea O
, O
upper O
abdominal O
pain O
, O
and O
vomiting O
( O
6.1 O
) O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
a O
rate O
at O
least O
twice O
placebo O
) O
in O
adults O
with O
BED O
were O
dry O
mouth O
, O
insomnia O
, O
decreased O
appetite O
, O
increased O
heart O
rate O
, O
constipation O
, O
feeling O
jittery O
, O
and O
anxiety O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Shire O
US O
Inc O
. O
at O
1-800-828-2088 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Attention B-Not_AE_Candidate
Deficit I-Not_AE_Candidate
Hyperactivity I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
The O
safety O
data O
in O
this O
section O
is O
based O
on O
data O
from O
the O
4-week O
parallel-group O
controlled O
clinical O
studies O
of O
VYVANSE O
in O
pediatric O
and O
adult O
patients O
with O
ADHD B-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
in O
ADHD O
Clinical O
Trials O
In O
the O
controlled O
trial O
in O
patients O
ages O
6 O
to O
12 O
years O
( O
Study O
1 O
) O
, O
8 O
% O
( O
18/218 O
) O
of O
VYVANSE-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
compared O
to O
0 O
% O
( O
0/72 O
) O
of O
placebo-treated O
patients O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
( O
1 O
% O
or O
more O
and O
twice O
rate O
of O
placebo O
) O
were O
ECG B-OSE_Labeled_AE
voltage I-OSE_Labeled_AE
criteria I-OSE_Labeled_AE
for I-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
, O
tic B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
hyperactivity I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
and O
rash B-OSE_Labeled_AE
[ O
2 O
instances O
for O
each O
adverse O
reaction O
, O
i.e. O
, O
2/218 O
( O
1 O
% O
) O
] O
. O

Less O
frequently O
reported O
adverse O
reactions O
( O
less O
than O
1 O
% O
or O
less O
than O
twice O
rate O
of O
placebo O
) O
included O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
logorrhea B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
anger B-OSE_Labeled_AE
and O
hypertension B-OSE_Labeled_AE
. O

In O
the O
controlled O
trial O
in O
patients O
ages O
13 O
to O
17 O
years O
( O
Study O
4 O
) O
, O
3 O
% O
( O
7/233 O
) O
of O
VYVANSE-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
compared O
to O
1 O
% O
( O
1/77 O
) O
of O
placebo-treated O
patients O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
( O
1 O
% O
or O
more O
and O
twice O
rate O
of O
placebo O
) O
were O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
( O
2/233 O
; O
1 O
% O
) O
and O
insomnia B-OSE_Labeled_AE
( O
2/233 O
; O
1 O
% O
) O
. O

Less O
frequently O
reported O
adverse O
reactions O
( O
less O
than O
1 O
% O
or O
less O
than O
twice O
rate O
of O
placebo O
) O
included O
irritability B-OSE_Labeled_AE
, O
dermatillomania B-OSE_Labeled_AE
, O
mood B-OSE_Labeled_AE
swings I-OSE_Labeled_AE
, O
and O
dyspnea B-OSE_Labeled_AE
. O

In O
the O
controlled O
adult O
trial O
( O
Study O
7 O
) O
, O
6 O
% O
( O
21/358 O
) O
of O
VYVANSE-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
compared O
to O
2 O
% O
( O
1/62 O
) O
of O
placebo-treated O
patients O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
( O
1 O
% O
or O
more O
and O
twice O
rate O
of O
placebo O
) O
were O
insomnia B-OSE_Labeled_AE
( O
8/358 O
; O
2 O
% O
) O
, O
tachycardia B-OSE_Labeled_AE
( O
3/358 O
; O
1 O
% O
) O
, O
irritability B-OSE_Labeled_AE
( O
2/358 O
; O
1 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
4/358 O
; O
1 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
2/358 O
; O
1 O
% O
) O
, O
anxiety B-OSE_Labeled_AE
( O
2/358 O
; O
1 O
% O
) O
, O
and O
dyspnea B-OSE_Labeled_AE
( O
3/358 O
; O
1 O
% O
) O
. O

Less O
frequently O
reported O
adverse O
reactions O
( O
less O
than O
1 O
% O
or O
less O
than O
twice O
rate O
of O
placebo O
) O
included O
palpitations B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
paranoia B-OSE_Labeled_AE
and O
restlessness B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
> O
=5 O
% O
or O
More O
Among O
VYVANSE O
Treated O
Patients O
with O
ADHD O
in O
Clinical O
Trials O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
at O
a O
rate O
at O
least O
twice O
placebo O
) O
reported O
in O
children O
, O
adolescents O
, O
and/or O
adults O
were O
anorexia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
abdominal I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
and O
vomiting B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
Among O
VYVANSE O
Treated O
Patients O
with O
ADHD O
in O
Clinical O
Trials O
Adverse O
reactions O
reported O
in O
the O
controlled O
trials O
in O
pediatric O
patients O
ages O
6 O
to O
12 O
years O
( O
Study O
1 O
) O
, O
adolescent O
patients O
ages O
13 O
to O
17 O
years O
( O
Study O
4 O
) O
, O
and O
adult O
patients O
( O
Study O
7 O
) O
treated O
with O
VYVANSE O
or O
placebo O
are O
presented O
in O
Tables O
1 O
, O
2 O
, O
and O
3 O
below O
. O

Table O
1 O
Adverse O
Reactions O
Reported O
by O
2 O
% O
or O
More O
of O
Children O
( O
Ages O
6 O
to O
12 O
Years O
) O
with O
ADHD O
Taking O
VYVANSE O
and O
at O
least O
Twice O
the O
Incidence O
in O
Patients O
Taking O
Placebo O
in O
a O
4-Week O
Clinical O
Trial O
( O
Study O
1 O
) O
VYVANSE O
( O
n=218 O
) O
Placebo O
( O
n=72 O
) O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
39 O
% O
4 O
% O
Insomnia B-OSE_Labeled_AE
22 O
% O
3 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Upper I-OSE_Labeled_AE
12 O
% O
6 O
% O
Irritability B-OSE_Labeled_AE
10 O
% O
0 O
% O
Vomiting B-OSE_Labeled_AE
9 O
% O
4 O
% O
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
9 O
% O
1 O
% O
Nausea B-OSE_Labeled_AE
6 O
% O
3 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
5 O
% O
0 O
% O
Dizziness B-OSE_Labeled_AE
5 O
% O
0 O
% O
Affect B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
3 O
% O
0 O
% O
Rash B-OSE_Labeled_AE
3 O
% O
0 O
% O
Pyrexia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Somnolence B-OSE_Labeled_AE
2 O
% O
1 O
% O
Tic B-OSE_Labeled_AE
2 O
% O
0 O
% O
Anorexia B-OSE_Labeled_AE
2 O
% O
0 O
% O
Table O
2 O
Adverse O
Reactions O
Reported O
by O
2 O
% O
or O
More O
of O
Adolescent O
( O
Ages O
13 O
to O
17 O
Years O
) O
Patients O
with O
ADHD O
Taking O
VYVANSE O
and O
at O
least O
Twice O
the O
Incidence O
in O
Patients O
Taking O
Placebo O
in O
a O
4-Week O
Clinical O
Trial O
( O
Study O
4 O
) O
VYVANSE O
( O
n=233 O
) O
Placebo O
( O
n=77 O
) O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
34 O
% O
3 O
% O
Insomnia B-OSE_Labeled_AE
13 O
% O
4 O
% O
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
9 O
% O
0 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
4 O
% O
1 O
% O
Palpitations B-OSE_Labeled_AE
2 O
% O
1 O
% O
Anorexia B-OSE_Labeled_AE
2 O
% O
0 O
% O
Tremor B-OSE_Labeled_AE
2 O
% O
0 O
% O
Table O
3 O
Adverse O
Reactions O
Reported O
by O
2 O
% O
or O
More O
of O
Adult O
Patients O
with O
ADHD O
Taking O
VYVANSE O
and O
at O
least O
Twice O
the O
Incidence O
in O
Patients O
Taking O
Placebo O
in O
a O
4-Week O
Clinical O
Trial O
( O
Study O
7 O
) O
VYVANSE O
( O
n=358 O
) O
Placebo O
( O
n=62 O
) O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
27 O
% O
2 O
% O
Insomnia B-OSE_Labeled_AE
27 O
% O
8 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
26 O
% O
3 O
% O
Diarrhea B-OSE_Labeled_AE
7 O
% O
0 O
% O
Nausea B-OSE_Labeled_AE
7 O
% O
0 O
% O
Anxiety B-OSE_Labeled_AE
6 O
% O
0 O
% O
Anorexia B-OSE_Labeled_AE
5 O
% O
0 O
% O
Feeling B-OSE_Labeled_AE
Jittery I-OSE_Labeled_AE
4 O
% O
0 O
% O
Agitation B-OSE_Labeled_AE
3 O
% O
0 O
% O
Increased B-OSE_Labeled_AE
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
3 O
% O
0 O
% O
Hyperhidrosis B-OSE_Labeled_AE
3 O
% O
0 O
% O
Restlessness B-OSE_Labeled_AE
3 O
% O
0 O
% O
Decreased B-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
3 O
% O
0 O
% O
Dyspnea B-OSE_Labeled_AE
2 O
% O
0 O
% O
Increased B-OSE_Labeled_AE
Heart I-OSE_Labeled_AE
Rate I-OSE_Labeled_AE
2 O
% O
0 O
% O
Tremor B-OSE_Labeled_AE
2 O
% O
0 O
% O
Palpitations B-OSE_Labeled_AE
2 O
% O
0 O
% O
In O
addition O
, O
in O
the O
adult O
population O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
was O
observed O
in O
2.6 O
% O
of O
males O
on O
VYVANSE O
and O
0 O
% O
on O
placebo O
; O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
was O
observed O
in O
1.4 O
% O
of O
subjects O
on O
VYVANSE O
and O
0 O
% O
on O
placebo O
. O

Weight O
Loss O
and O
Slowing O
Growth O
Rate O
in O
Pediatric O
Patients O
with O
ADHD O
In O
a O
controlled O
trial O
of O
VYVANSE O
in O
children O
ages O
6 O
to O
12 O
years O
( O
Study O
1 O
) O
, O
mean O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
from O
baseline O
after O
4 O
weeks O
of O
therapy O
was O
-0.9 O
, O
-1.9 O
, O
and O
-2.5 O
pounds O
, O
respectively O
, O
for O
patients O
receiving O
30 O
mg O
, O
50 O
mg O
, O
and O
70 O
mg O
of O
VYVANSE O
, O
compared O
to O
a O
1 O
pound O
weight B-NonOSE_AE
gain I-NonOSE_AE
for O
patients O
receiving O
placebo O
. O

Higher O
doses O
were O
associated O
with O
greater O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
with O
4 O
weeks O
of O
treatment O
. O

Careful O
follow-up O
for O
weight O
in O
children O
ages O
6 O
to O
12 O
years O
who O
received O
VYVANSE O
over O
12 O
months O
suggests O
that O
consistently O
medicated O
children O
( O
i.e O
. O

treatment O
for O
7 O
days O
per O
week O
throughout O
the O
year O
) O
have O
a O
slowing B-OSE_Labeled_AE
in I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
measured O
by O
body O
weight O
as O
demonstrated O
by O
an O
age- O
and O
sex-normalized O
mean O
change O
from O
baseline O
in O
percentile O
, O
of O
-13.4 O
over O
1 O
year O
( O
average O
percentiles O
at O
baseline O
and O
12 O
months O
were O
60.9 O
and O
47.2 O
, O
respectively O
) O
. O

In O
a O
4-week O
controlled O
trial O
of O
VYVANSE O
in O
adolescents O
ages O
13 O
to O
17 O
years O
, O
mean O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
from O
baseline O
to O
endpoint O
was O
-2.7 O
, O
-4.3 O
, O
and O
-4.8 O
lbs. O
, O
respectively O
, O
for O
patients O
receiving O
30 O
mg O
, O
50 O
mg O
, O
and O
70 O
mg O
of O
VYVANSE O
, O
compared O
to O
a O
2.0 O
pound O
weight B-NonOSE_AE
gain I-NonOSE_AE
for O
patients O
receiving O
placebo O
. O

Careful O
follow-up O
of O
weight O
and O
height O
in O
children O
ages O
7 O
to O
10 O
years O
who O
were O
randomized O
to O
either O
methylphenidate O
or O
non-medication O
treatment O
groups O
over O
14 O
months O
, O
as O
well O
as O
in O
naturalistic O
subgroups O
of O
newly O
methylphenidate-treated O
and O
non-medication O
treated O
children O
over O
36 O
months O
( O
to O
the O
ages O
of O
10 O
to O
13 O
years O
) O
, O
suggests O
that O
consistently O
medicated O
children O
( O
i.e O
. O

treatment O
for O
7 O
days O
per O
week O
throughout O
the O
year O
) O
have O
a O
temporary O
slowing B-OSE_Labeled_AE
in I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
( O
on O
average O
, O
a O
total O
of O
about O
2 B-OSE_Labeled_AE
cm I-OSE_Labeled_AE
less I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
height I-OSE_Labeled_AE
and O
2 B-OSE_Labeled_AE
. I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
less I-OSE_Labeled_AE
growth I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
over O
3 O
years O
) O
, O
without O
evidence O
of O
growth O
rebound O
during O
this O
period O
of O
development O
. O

In O
a O
controlled O
trial O
of O
amphetamine O
( O
d- O
to O
l-enantiomer O
ratio O
of O
3:1 O
) O
in O
adolescents O
, O
mean O
weight B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from O
baseline O
within O
the O
initial O
4 O
weeks O
of O
therapy O
was O
-1.1 O
pounds O
and O
-2.8 O
pounds O
, O
respectively O
, O
for O
patients O
receiving O
10 O
mg O
and O
20 O
mg O
of O
amphetamine O
. O

Higher O
doses O
were O
associated O
with O
greater O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
within O
the O
initial O
4 O
weeks O
of O
treatment O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Weight O
Loss O
in O
Adults O
with O
ADHD O
In O
the O
controlled O
adult O
trial O
( O
Study O
7 O
) O
, O
mean O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
after O
4 O
weeks O
of O
therapy O
was O
2.8 O
pounds O
, O
3.1 O
pounds O
, O
and O
4.3 O
pounds O
, O
for O
patients O
receiving O
final O
doses O
of O
30 O
mg O
, O
50 O
mg O
, O
and O
70 O
mg O
of O
VYVANSE O
, O
respectively O
, O
compared O
to O
a O
mean O
weight B-NonOSE_AE
gain I-NonOSE_AE
of O
0.5 O
pounds O
for O
patients O
receiving O
placebo O
. O

Binge B-Not_AE_Candidate
Eating I-Not_AE_Candidate
Disorder I-Not_AE_Candidate
The O
safety O
data O
in O
this O
section O
is O
based O
on O
data O
from O
two O
12 O
week O
parallel O
group O
, O
flexible-dose O
, O
placebo-controlled O
studies O
in O
adults O
with O
BED B-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
14.2 O
] O
. O

Patients O
with O
cardiovascular O
risk O
factors O
other O
than O
obesity B-Not_AE_Candidate
and O
smoking O
were O
excluded O
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
in O
BED O
Clinical O
Trials O
In O
controlled O
trials O
of O
patients O
ages O
18 O
to O
55 O
years O
, O
5.1 O
% O
( O
19/373 O
) O
of O
VYVANSE-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
compared O
to O
2.4 O
% O
( O
9/372 O
) O
of O
placebo-treated O
patients O
. O

No O
single O
adverse O
reaction O
led O
to O
discontinuation O
in O
1 O
% O
or O
more O
of O
VYVANSE-treated O
patients O
. O

Less O
commonly O
reported O
adverse O
reactions O
( O
less O
than O
1 O
% O
or O
less O
than O
twice O
rate O
of O
placebo O
) O
included O
increased B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
jittery I-OSE_Labeled_AE
and O
anxiety B-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
=5 O
% O
and O
at O
a O
rate O
at O
least O
twice O
placebo O
) O
reported O
in O
adults O
were O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
feeling B-OSE_Labeled_AE
jittery I-OSE_Labeled_AE
, O
and O
anxiety B-OSE_Labeled_AE
. O

Adverse O
reactions O
reported O
in O
the O
pooled O
controlled O
trials O
in O
adult O
patients O
( O
Study O
11 O
and O
12 O
) O
treated O
with O
VYVANSE O
or O
placebo O
are O
presented O
in O
Table O
4 O
below O
. O

Table O
4 O
Adverse O
Reactions O
Reported O
by O
2 O
% O
or O
More O
of O
Adult O
Patients O
with O
BED O
Taking O
VYVANSE O
and O
at O
least O
Twice O
the O
Incidence O
in O
Patients O
Taking O
Placebo O
in O
12-Week O
Clinical O
Trials O
( O
Study O
11 O
and O
12 O
) O
VYVANSE O
( O
N=373 O
) O
Placebo O
( O
N=372 O
) O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
36 O
% O
7 O
% O
Insomnia B-OSE_Labeled_AE
[ O
note O
: O
Includes O
all O
preferred O
terms O
containing O
the O
word O
" B-OSE_Labeled_AE
insomnia I-OSE_Labeled_AE
. O
'' O
] O

20 O
% O
8 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
8 O
% O
2 O
% O
Increased B-OSE_Labeled_AE
Heart I-OSE_Labeled_AE
Rate I-OSE_Labeled_AE
[ O
note O
: O
Includes O
the O
preferred O
terms O
`` O
heart B-OSE_Labeled_AE
rate I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
`` O
and O
`` O
tachycardia B-OSE_Labeled_AE
. O
'' O
] O

7 O
% O
1 O
% O
Feeling B-OSE_Labeled_AE
Jittery I-OSE_Labeled_AE
6 O
% O
1 O
% O
Constipation B-OSE_Labeled_AE
6 O
% O
1 O
% O
Anxiety B-OSE_Labeled_AE
5 O
% O
1 O
% O
Diarrhea B-OSE_Labeled_AE
4 O
% O
2 O
% O
Decreased B-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
4 O
% O
0 O
% O
Hyperhidrosis B-OSE_Labeled_AE
4 O
% O
0 O
% O
Vomiting B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastroenteritis B-OSE_Labeled_AE
2 O
% O
1 O
% O
Paresthesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Pruritis B-OSE_Labeled_AE
2 O
% O
1 O
% O
Upper B-OSE_Labeled_AE
Abdominal I-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
0 O
% O
Energy B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
2 O
% O
0 O
% O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
2 O
% O
0 O
% O
Nightmare B-OSE_Labeled_AE
2 O
% O
0 O
% O
Restlessness B-OSE_Labeled_AE
2 O
% O
0 O
% O
Oropharyngeal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
% O
0 O
% O
6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
VYVANSE O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

These O
events O
are O
as O
follows O
: O
cardiomyopathy B-OSE_Labeled_AE
, O
mydriasis B-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
difficulties B-OSE_Labeled_AE
with I-OSE_Labeled_AE
visual I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
, O
eosinophilic B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
hypersensitivity B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
tics B-OSE_Labeled_AE
, O
bruxism B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
dermatillomania B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
aggression B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
seizures B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
frequent B-OSE_Labeled_AE
or O
prolonged O
erections I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
and O
rhabdomyolysis B-OSE_Labeled_AE
. O

